Sellas Life Sciences Group (Sellas) has reported positive topline Phase I results for its cancer vaccine, galinpepimut-S (GPS), in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) in relapsed or refractory malignant pleural mesothelioma (MPM).

Sellas CEO Angelos Stergiou stated: “In our GPS trials completed in previous years, we have observed and reported increased survival in the maintenance therapy setting, which is the primary setting for our GPS therapy.

“This year, we have seen in two studies where GPS appears to increase the survival benefit in active disease when combined with checkpoint blockade drugs, one with relapsed/refractory WT1 positive ovarian cancer and now in relapsed/refractory WT1 positive mesothelioma.”

GlobalData forecasts the global sales for therapeutic cancer vaccines to reach $4bn by 2028.

GlobalDala is the parent company of Clinical Trials Arena.

GPS is also being investigated in an open-label Phase I/II study (NCT03761914) as a combination therapy with MSD’s Keytruda for other advanced cancers, including acute myelogenous leukaemia, and ovarian cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Phase I data

The open-label, single-group Phase I study (NCT04040231) enrolled ten patients with MPM in the US, nine of whom received the study-specified combination therapy.

The median survival rate was 17.6 months in the nine patients, with a median overall survival of 15.6 months in patients with stage IV MPM (four patients) at the start of the study.

A number of adverse events were observed by all the patients during the study. Treatment-related toxicities were observed in seven patients, with six reporting Opdivo toxicity. Severe adverse events requiring hospitalisation were reported in three cases. Three GPS-related mild adverse events were also observed.

Additional immune response data is expected by the fourth quarter of 2023.